Delivering HIV-1 antibodies using hydrogel microparticles
Official title: High-Dose and Sustained Delivery of HIV-1 Broadly Neutralizing Antibodies via Subcutaneous Injection of Hydrogel-based Microparticle Formations
Funded at Acousticabio, INC. · NIH-11171824 · Data updated 2026-11-12
This study is testing a new way to give HIV-1 patients long-lasting treatment using special injections that release powerful antibodies over time, making it easier and more effective to fight the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acousticabio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,116 |
| NIH project number | 75N93024C00047-0-9999-1 |
| Project ID | NIH-11171824 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV-1 who are seeking innovative treatment options.
✕Less likely to help
Patients who are not infected with HIV-1 or those who do not respond to antibody therapies may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver broadly neutralizing antibodies (bNAbs) for HIV-1 treatment through subcutaneous injections of hydrogel-based microparticles. By enhancing the potency and extending the half-life of these antibodies, the goal is to improve their effectiveness against the diverse strains of HIV-1. The project aims to create a sustained-release formulation that can provide long-lasting protection from infection, potentially reducing the frequency of injections needed. Patients may benefit from a more effective and convenient treatment option.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and long-lasting treatment option for HIV-1.
How similar studies have gone: Previous research has shown success with antibody-mediated prevention strategies, indicating potential for this novel approach.
Where this research is happening
-
Acousticabio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Foresti, Daniele — Acousticabio, INC.
- Study coordinator: Foresti, Daniele
Related research
Other NIH-funded projects on the same topics.
-
Subcutaneous delivery of monoclonal antibodies using microgel formulations
A new approach uses tiny gel particles to deliver antibody medicines under the skin instead of through IV, aiming to be faster, more comfortable, and potentially cheaper.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.